BioCryst Announces Positive Phase 1 Results with BCX9250

We're pleased to share this announcement about the positive Phase 1 trial results of the first in-humans study of BioCryst's ALK-2 Inhibitor for the treatment of FOP. Read BioCryst's press release.

Make a Difference

Donate Connect Fundraise

Already a Member? Sign In

Sign Up for FOP Connection, Our Monthly eNewsletter